Surfactant therapy for bronchiolitis in critically ill infants (Q24245016)

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

The association of apnea and respiratory syncytial virus infection in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Surfactant protein-A enhances uptake of respiratory syncytial virus by monocytes and U937 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Respiratory syncytial virus infections in the pediatric intensive care unit: clinical characteristics and risk factors for adverse outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Genetic polymorphisms in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Surfactant abnormalities in infants with severe viral bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Bronchiolitis: what's next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Quality of Reporting of Randomized Trials as a Measure of Methodologic Quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

The hazards of scoring the quality of clinical trials for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Surfactant protein levels in severe respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Surfactant protein-d enhances phagocytosis and pulmonary clearance of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

The feasibility of conducting clinical trials in infants and children with acute respiratory failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Response to exogenous surfactant is different during open lung and conventional ventilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Additivity of protein and nonprotein inhibitors of lung surfactant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Pulmonary surfactant: a front line of lung host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

Pulmonary surfactant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

7 January 2021

Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

7 January 2021

Different ventilation strategies alter surfactant responses in preterm rabbits

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

7 January 2021

Tidal volume effects on surfactant treatment responses with the initiation of ventilation in preterm lambs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

7 January 2021

Human surfactant protein B: structure, function, regulation, and genetic disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

7 January 2021

Immunomodulatory functions of surfactant

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

7 January 2021

Ventilation strategies affect surfactant aggregate conversion in acute lung injury

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

7 January 2021

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005150.PUB2

7 January 2021